Guardant Health, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $982.0M | $739.0M | $563.9M | $449.5M | $373.7M |
| Cost of revenue | $349.0M | $289.8M | $227.1M | — | — |
| Research and development | $364.2M | $347.8M | $367.2M | $373.8M | $263.2M |
| Operating income | -$437.2M | -$443.6M | -$564.7M | -$544.4M | -$411.0M |
| Interest expense | $3.9M | $2.6M | $2.6M | $2.6M | $2.6M |
| Pretax income | -$417.5M | -$435.1M | -$478.8M | -$653.4M | -$384.5M |
| Income tax expense | -$1.3M | $1.3M | $685,000 | $1.1M | $300,000 |
| Net income | -$416.3M | -$436.4M | -$479.4M | -$654.6M | -$384.8M |
| Balance Sheet | |||||
| Cash and equivalents | $378.2M | $525.5M | $1.1B | $141.6M | $492.2M |
| Current assets | $1.5B | $1.1B | $1.3B | $1.2B | $1.1B |
| Total assets | $2.0B | $1.5B | $1.8B | $1.6B | $2.2B |
| Current liabilities | $302.7M | $225.6M | $205.9M | $193.2M | $194.7M |
| Total liabilities | $2.1B | $1.6B | $1.6B | $1.5B | $1.6B |
| Stockholders' equity | -$99.3M | -$139.6M | $158.7M | $60.2M | $645.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$184.8M | -$239.9M | -$325.0M | -$309.5M | -$209.0M |
| Depreciation and amortization | $39.7M | $42.4M | $42.9M | $36.0M | $22.3M |
| Stock-based compensation | $166.2M | $140.4M | $90.8M | $94.7M | $151.4M |
| Capital expenditure | $48.3M | $35.1M | $20.5M | $77.5M | $75.0M |
| Free cash flow | -$233.1M | -$274.9M | -$345.5M | -$386.9M | -$284.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Share repurchases | $45.0M | $0 | $0 | — | — |
| Impairments | $0 | — | — | — | — |
Shares outstanding 132.6M · Free float 69.2%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.